These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22538771)

  • 21. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers.
    Zuo T; Wilson P; Cicek AF; Harigopal M
    Hum Pathol; 2018 Oct; 80():239-245. PubMed ID: 29902579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
    Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
    Vaziri SA; Krumroy LM; Elson P; Budd GT; Darlington G; Myles J; Tubbs RR; Casey G
    Clin Cancer Res; 2001 Jul; 7(7):1937-45. PubMed ID: 11448907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
    Thike AA; Tan PH; Ikeda M; Iqbal J
    Histopathology; 2016 Apr; 68(5):702-12. PubMed ID: 26259780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast cancer in the elderly: a histological assessment.
    Tse GM; Tan PH; Lau KM; de Andrade VP; Lui PC; Vong JS; Chaiwun B; Lam CC; Yu AM; Moriya T
    Histopathology; 2009 Oct; 55(4):441-51. PubMed ID: 19817895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
    Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
    Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers.
    Choi J; Jung WH; Koo JS
    Histol Histopathol; 2012 Nov; 27(11):1481-93. PubMed ID: 23018247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumoral expression of BRCA1, estrogen receptor alpha and ID4 protein in patients with sporadic breast cancer.
    Roldán G; Delgado L; Musé IM
    Cancer Biol Ther; 2006 May; 5(5):505-10. PubMed ID: 16582598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of androgen receptors in triple negative breast carcinomas.
    Mrklić I; Pogorelić Z; Capkun V; Tomić S
    Acta Histochem; 2013 May; 115(4):344-8. PubMed ID: 23031358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are bilateral breast cancers different from breast cancers coexisting with ovarian cancer? An immunohistochemical analysis aimed at intrinsic tumor phenotype.
    Senkus E; Szade J; Pieczyńska B; Żaczek A; Brożek I; Radecka B; Kowalczyk A; Wełnicka-Jaśkiewicz M; Jassem J
    Breast; 2013 Aug; 22(4):425-30. PubMed ID: 23642527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA1 protein expression and its correlation with ER/PR status in sporadic and familial breast cancer in Eastern Indian patients--a hospital based study.
    Ashraf M; Jha JK; Mukherjee N; Panda CK; Nayak S; Jadhav TS; Dikshit N; Nath NC; Chakraborty J; Biswas J
    J Indian Med Assoc; 2011 Dec; 109(12):873-8. PubMed ID: 23469566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
    van der Groep P; van Diest PJ; Menko FH; Bart J; de Vries EG; van der Wall E
    J Clin Pathol; 2009 Oct; 62(10):926-30. PubMed ID: 19541683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
    Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
    Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies.
    Siziopikou KP; Cobleigh M
    Breast; 2007 Feb; 16(1):104-7. PubMed ID: 17097880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of triple-negative and basal-like canine mammary carcinomas using four basal markers.
    Kim NH; Lim HY; Im KS; Kim JH; Sur JH
    J Comp Pathol; 2013 May; 148(4):298-306. PubMed ID: 23079102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype.
    Santarosa M; Maestro R
    Cancer Metastasis Rev; 2012 Jun; 31(1-2):131-42. PubMed ID: 22101651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
    Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
    Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma.
    Sutton LM; Han JS; Molberg KH; Sarode VR; Cao D; Rakheja D; Sailors J; Peng Y
    Am J Clin Pathol; 2010 Nov; 134(5):782-7. PubMed ID: 20959661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.